Oliceridine

Summary

Oliceridine (CHEMBL2443262) is an approved small molecule (ATC N02AX07); indicated across 1 condition.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N02AX07
• Indications: 1 condition
• Clinical trials: 24
• Chemistry: 386.6 Da · C22H30N2O2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2443262
Name	Oliceridine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	66553195
ATC	N02AX07
Molecular formula	C22H30N2O2S
Molecular weight	386.6
InChIKey	DMNOVGJWPASQDL-OAQYLSRUSA-N

SMILES: COC1=C(SC=C1)CNCC[C@]2(CCOC3(C2)CCCC3)C4=CC=CC=N4

IUPAC name: N-[(3-methoxythiophen-2-yl)methyl]-2-[(9R)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethanamine

Also known as: Oliceridina, Oliceridine, Olinvyk, Olynvik, TRV-130, TRV130, OLICERIDINE, OLICERIDINE (HYDROCHLORIDE), Oliceridine (hydrochloride)

Parent form; salt/anhydrous children: CHEMBL6068518

Patent coverage: 137 distinct patent families (343 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 282 (82%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 11 (assay-derived). Sample: Voltage-dependent L-type calcium channel subunit alpha-1C, Sodium channel protein type 5 subunit alpha, D(2) dopamine receptor, Mu-type opioid receptor, D(3) dopamine receptor, Delta-type opioid receptor, Kappa-type opioid receptor, Voltage-gated inwardly rectifying potassium channel KCNH2, Mu-type opioid receptor, Cytochrome P450 2D6.

Bioactivity

ChEMBL activities: 25 potent at pChembl ≥ 5 of 29 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
OPRM1	8.84	Ki	1.46	nM	CHEMBL_ACT_24399183
OPRM1	8.74	EC50	1.8	nM	CHEMBL_ACT_24399069
P42866	8.62	EC50	2.4	nM	CHEMBL_ACT_25621804
P42866	8.62	EC50	2.4	nM	CHEMBL_ACT_25621805
OPRM1	8.52	EC50	3	nM	CHEMBL_ACT_28505294
OPRM1	8.36	Ki	4.38	nM	CHEMBL_ACT_25621603
OPRM1	8.22	Ki	6	nM	CHEMBL_ACT_13515283
OPRM1	8.17	EC50	6.7	nM	CHEMBL_ACT_24399186
OPRM1	8.1	EC50	8	nM	CHEMBL_ACT_13515280
OPRM1	8.1	EC50	7.94	nM	CHEMBL_ACT_13515427
OPRM1	7.92	EC50	12	nM	CHEMBL_ACT_24399207
OPRM1	7.57	Ki	27	nM	CHEMBL_ACT_28840151
P42866	7.49	EC50	32.36	nM	CHEMBL_ACT_25621843
P42866	7.49	EC50	32.5	nM	CHEMBL_ACT_25621844
OPRM1	7.3	EC50	50.12	nM	CHEMBL_ACT_13515356
P42866	7.23	EC50	58.88	nM	CHEMBL_ACT_25621757
P42866	7.23	EC50	58.5	nM	CHEMBL_ACT_25621758
OPRK1	5.85	EC50	1400	nM	CHEMBL_ACT_13515299
OPRD1	5.55	EC50	2800	nM	CHEMBL_ACT_13515297
CYP2D6	5.34	IC50	4600	nM	CHEMBL_ACT_28505405
SCN5A	5.33	IC50	4700	nM	CHEMBL_ACT_13515287
KCNH2	5.26	IC50	5500	nM	CHEMBL_ACT_24399166
KCNH2	5.26	IC50	5500	nM	CHEMBL_ACT_28505546
KCNH2	5.21	IC50	6200	nM	CHEMBL_ACT_13515289
DRD3	5.16	Ki	6860	nM	CHEMBL_ACT_25621696

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4).

The 1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 24.

Phase distribution

Phase	Trials
Not specified	8
PHASE4	7
PHASE3	3
PHASE2	3
PHASE1	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06411665	PHASE4	RECRUITING	Effect of Oliceridine Analgesia on Postoperative Nause and Vomiting
NCT07018375	PHASE4	NOT_YET_RECRUITING	The Effect of Oliceridine Patient-Controlled Intravenous Analgesia on Postoperative Chronic Pain After Video-Assisted Thoracoscopic Lobectomy
NCT07026162	PHASE4	RECRUITING	Oliceridine on Postoperative Nausea and Vomiting in Gynecological Laparoscopic Surgery
NCT04979247	PHASE4	COMPLETED	Intravenous Oliceridine and Opioid-related Complications
NCT05465226	PHASE4	COMPLETED	Oliceridine in Patients With Acute Burn Injuries
NCT06458400	PHASE4	COMPLETED	To Evaluate the Efficacy and Safety of Tegileridine and Oliceridine Injections in the Treatment of Postoperative Pain
NCT07306702	PHASE4	WITHDRAWN	Dexmedetomidine-Enhanced PCIA After Lobectomy in Nicotine-Dependent Patients
NCT02656875	PHASE3	COMPLETED	A Open-label Study to Evaluate the Safety of TRV130 in Patients With Acute Pain
NCT02815709	PHASE3	COMPLETED	Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Bunionectomy
NCT02820324	PHASE3	COMPLETED	Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Abdominoplasty
NCT02100748	PHASE2	COMPLETED	A Study of TRV130 for the Treatment of Pain After Bunionectomy
NCT02335294	PHASE2	COMPLETED	A Study of TRV130 for the Treatment of Pain After Abdominoplasty
NCT02520297	PHASE2	TERMINATED	A Pilot Study of TRV130 for the Treatment of Fracture Pain
NCT02083315	PHASE1	COMPLETED	Pharmacokinetics and Pharmacodynamics of TRV130, Morphine, and Placebo in Healthy Subjects
NCT02169934	PHASE1	COMPLETED	A Study to Investigate the Metabolism and Excretion of [14C]-TRV130 in Healthy Male Subjects
NCT02344303	PHASE1	COMPLETED	Study of the Effects of TRV130, at Therapeutic and Supra Therapeutic Doses, on QTc Intervals
NCT06668298	Not specified	NOT_YET_RECRUITING	Clinical Study of G Protein Biased Μ - Opioid Receptor Agonist Oliceridine for Optimizing Postoperative Analgesia Under General Anesthesia
NCT06990893	Not specified	RECRUITING	Comparison of the Analgesic Effect of Oliceridine Versus Morphine or Sufentanil for Postoperative Analgesia in Lumbar Surgeries: a Randomized Control Trial
NCT07097038	Not specified	NOT_YET_RECRUITING	Analgesic Effect and Safety of Oliceridine and Oxycodone in Vitrectomy
NCT07112157	Not specified	NOT_YET_RECRUITING	Efficacy of Oxalidine and Sufentanil in Strabismus Correction
NCT07479446	Not specified	RECRUITING	Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery
NCT07154979	Not specified	COMPLETED	Oliceridine Dose for Tracheal Intubation Hemodynamic Elevation: Up-and-Down Trial
NCT07187765	Not specified	COMPLETED	Respiratory Safety of Oliceridine During Sedated Gastrointestinal Endoscopy
NCT07372209	Not specified	COMPLETED	Effects and Safety of Oliceridine in Anesthesia Induction:A Randomised Controlled Trial

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).